Madrigal Pharmaceuticals, Inc. MDGL Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s change in accrued liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported change in accrued liabilities of $4.29M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s change in accrued liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s change in accrued liabilities increased by 908.9% year-over-year, from -$530K to $4.29M.
- What does change in accrued liabilities mean?
- The net change in money the company owes for services or goods already received but not yet paid.
- How do you interpret change in accrued liabilities?
- An increase suggests deferred cash outflows or rising operational obligations, while a decrease indicates the settlement of prior liabilities.
- How does change in accrued liabilities compare across companies?
- Commonly tracked across all industries as a component of working capital changes.